Delayed market entry of blockbuster pharmaceutical

Delayed market entry of blockbuster pharmaceutical

Timothy Snail
Health Care | Life Sciences
Antitrust & Competition | Damages & Valuation

In a matter involving an antitrust counterclaim, a generic pharmaceutical manufacturer alleged that a blockbuster brand manufacturer attempted to monopolize the market and delay entry of the generic product. A CRA expert was retained to analyze market definition, competitive effects, and lost profits damages estimates. The matter settled favorably for our client shortly before trial.